Search results
Results from the WOW.Com Content Network
The Biomedical Advanced Research and Development Authority (BARDA) is a center within the Administration for Strategic Preparedness and Response [1] (ASPR) located within the U.S. Department of Health and Human Services (HHS) responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear ...
The Comprehensive Everglades Restoration Plan (CERP) is the plan enacted by the U.S. Congress for the restoration of the Everglades ecosystem in southern Florida. When originally authorized by the U.S. Congress in 2000, it was estimated that CERP would cost a total of $8.2 billion and take approximately 30 years to complete. More recent ...
The Everglades Foundation is dedicated to restoring and protecting America's Everglades through science, advocacy, and education, thereby advancing an understanding of the Greater Everglades ecosystem and its irreplaceable environmental and economic value. The organization is funded primarily from private donations.
This funding from BARDA will assist us in determining whether we can bring a transformational, next-generation approach to global vaccination,” said Steven Lo, Vaxart’s Chief Executive Officer.
The new award follows a $483 million grant provided by BARDA in April, which means Moderna has now received a total of $955 million in funding from the U.S. government.The award coincides with the ...
This BARDA funding will also be used to study HOPO-101 as a possible treatment for lead poisoning. As recently highlighted by several leading global health organizations including the U.S. Agency for International Development (USAID), lead poisoning kills an estimated 1.5 million people each year, more than malaria and HIV combined.
The Biomedical Advanced Research and Development Authority (BARDA) has issued an $8.6 million contract to OraSure Technologies Inc (NASDAQ: OSUR) for developing a 2nd generation Ebola test on the ...
Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed; Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule